As polypharmacology approaches may result in long-awaited breakthroughs in AD treatment, a computer-aided and visual analysis of the possibility of designing molecules with as yet unreported action via both 5-HT6R and the AD pathology-related kinase (MARK4, ROCKI/II or CDK5) within this paper has been performed. The gene discussed is MARK4; the disease is Alzheimer disease.